Polyphor AG (POLN) CHF2
Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas infections; the Outer Membrane Protein Targeting Antibiotics (OMPTA), which provides treatment options to treat infections caused by Gram-negative bacteria; POL6014 is inhaled elastase inhibitor for the treatment of Cystic Fibrosis and other neutrophilic lung diseases, as well as Balixafortide (POL6326) is a blocker of tumor growth and metastasis. The Company develops Macrocycle discovery platform, which includes library consisted of over 50,000 single, untagged, individually purified peptidic and non-peptidic macrocycles readily amenable to all screening formats, including binding, enzymatic, cellular, pathway and phenotypical.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.